Retatrutide

Eli Lilly's chief executive said the company's future has 'never been brighter' as it bets on retatrutide, its experimental obesity and weight-loss drug, to become the next major growth driver. The remark signals confidence that Lilly will extend its lead in the booming weight-loss medicine market alongside its existing blockbuster drugs, keeping investors focused on the drug's development and approval prospects.